China's GLP-1 moment: from domestic capacity build-out to a wave of global deals

The story of China's weight loss drug market is evolving from local competition to global ambition. What's their strategy beyond the lab?

As giants like Novo Nordisk and Eli Lilly invest billions to ramp up production, leading Chinese biotechs like Innovent and Sciwind are responding by forging their own path. Recent deals with AstraZeneca and Merck—worth billions—signal a paradigm shift: China's GLP-1 innovation is now commanding global recognition and premium deal terms.

Explore how R&D strength is translating into international success in our latest VBtalk.

Watch the previous video: Innovation drives China's weight loss drug market surge